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Deflazacort (DFZ) is claimed to have fewer adverse bone effects than prednisone (PDN) at doses with 
equivalent anti-inflammatory activity (5 mg PDN=6 mg DFZ). However, its safety over the long-term 
has never been tested in a controlled trial. 
The aim of the present study was to assess prospectively the safety and efficacy of DFZ compared with 
PDN in previously untreated patients with chronic, histologically proven sarcoidosis needing long-term 
(2 2 yr) corticosteroid therapy. 
Thirty-six patients were treated with PDN for 32 * 18 months and 36 patients were treated with DFZ 
for 42 f 18 months, and followed-up with periodic chest X-ray, 67Gallium lung scan, angiotensin 
converting enzyme (ACE), serum and urinary calcium levels, spirometry, alveolar diffusion (DLCO) 
arterial oxygen tension (PaO,), bone mineral content (BMC) (by computed tomography), and a 
complete biochemical and haematological profile. The two groups were similar as regards sex, age, 
pulmonary and extrapulmonary involvement, parameters of activity and impairment, and initial BMC. 
Daily starting doses were 23.2 f 11.4 mg DFZ and 22.3 & 6.9 mg PDN. 
One year of trial was completed by 69 patients, 2 yr by 59 patients, 3 yr by 46 patients and 4 yr by 
24 patients. Some patients were followed-up for 5-7 yr. The mean daily dose over the whole period was 
15 * 10 mg DFZ and 10 f 6 PDN, starting from 21 f 9 and 15 & 8 mg in the first year, and progressively 
declining to a mean of 9 f 6 mg in both groups in the fourth year. Chest X-ray, 67Ga score, ACE and 
forced vital capacity improved significantly in both groups. Urine total calcium improved significantly in 
the PDN group (345 f 27 to 186 * 47; PcO.05) with a similar but non-significant pattern in the DFZ 
group (270 + 28 to 207 & 39). Non-significant improvements were observed in DLCO, PaO, and forced 
expiratory volume in 1 s in both groups. 
Drug-related adverse events were more frequent in the PDN group, causing discontinuation of the 
drug in four PDN patients. Body weight increased mainly in the PDN group [69.9 & 0.4 to 73.6 LL 0.8 kg 
vs 70.1 f 0.4 to 70.0 f 0.6 kg in the DFZ group (P<O.Ol)]. Bone mineral content dropped under the 
fracture threshold in most PDN patients, who thus appeared at higher risk for fractures. In fact, six 
atraumatic skeletal fractures were observed in this group but only one in the DFZ group. Two further 
patients in the DFZ group and eight in the PDN group were obliged to start corrective measures for 
bone loss and/or bone pain. At the end of the study, 21 patients (12 DFZ, nine PDN) no longer needed 
corticosteroids, and the others were taking a maintenance daily dose that controlled the disease 
adequately. 
In conclusion, DFZ appeared as effective as PDN in the long-term treatment of chronic sarcoidosis, 
and it may have fewer side-effects, especially on bone. 
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Sarcoidosis is a systemic inflammatory disorder of 
unknown aetiology characterized by granulomas in 
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various organs. Although the clinical characteristics 
and pathology are well defined, the optimal therapy 
remains unclear and unspecific. Corticosteroids are 
generally considered beneficial although there is no 
single criterion for establishing the indications and 
duration of treatment, the maximal effective dose, or 
even the real effect of therapy on the natural history 
of the disease. Furthermore, the long-term use of 
these drugs may result in significant adverse events, 
osteoporosis being the most disabling. 
Deflazacort (DFZ), a methyl-oxazoline derivative 
of prednisolone, has been claimed to have anti- 
inflammatory activity comparable to prednisone 
(PDN), with less deleterious effect on the bone cal- 
cium metabolism, as evaluated in five long-term con- 
trolled trials with dual photon absorptiometry 
measurements of the lumbar spine (l-4), and histo- 
morphometric measurements of bone biopsy at the 
iliac crest (5). Three double-blind trials were carried 
out on homogeneous populations of patients with 
rheumatoid arthritis (2), juvenile chronic arthritis (3) 
and nephrotic syndrome (4). Two single-blind trials 
were carried out in less homogeneous groups of 
patients with sarcoidosis, collagen diseases, asthma 
and other immune-mediated diseases (1,5). All these 
trials lasted for at least 1 yr, some patients being 
studied for up to 18 months. In another controlled 
double-blind trial, patients with chronic inflamma- 
tory disorders were followed-up for 3 months; DFZ, 
at doses with the same anti-inflammatory activity as 
PDN, had fewer adverse effects on calcium and 
cortisol levels (6). All these trials provided ample 
information on the bone variables but scanty data on 
the long-term safety of DFZ compared to PDN. 
In an uncontrolled study on 40 patients followed- 
up for l-5 yr, DFZ was a good and safe approach for 
the long-term therapy of sarcoidosis (7). In another 
controlled trial lasting 6 months, DFZ was found to 
be as useful as PDN in suppressing sarcoid activity 
(8). 
In 1987, the present trial was started with the aim 
of comparing the long-term efficacy and safety of 
DFZ and PDN in chronic sarcoidosis requiring long- 
term corticosteroid therapy. The major end-point was 
to evaluate the reduction in bone mass and the 
increase in fractures in those steroid-treated patients. 
Methods 
STUDY DESIGN 
For the requirements of statistical evaluation (see 
later), 72 patients were needed. Accordingly, all 
patients satisfying the following admission criteria 
were eligible: 
(1) Histologically proven chronic sarcoidosis: 
(2) Need for long-term corticosteroid therapy; 
(3) No previous corticosteroid therapy; 
(4) Bone mineral content (BMC) not lower than 2 SD 
below the average reference value (z-score - 2 or 
less); and 
(5) No diseases affecting bone metabolism. 
Pulmonary sarcoidosis clears without therapy in 
over 50% of patients within 2 yr, but patients with 
chronic disease were chosen for study, in whom this 
probability is very low (see Table 1). The authors’ 
criteria for long-term therapy have been outlined in a 
previous paper (9). Briefly, corticosteroid therapy is 
started when there is clinical evidence of both sarcoid 
activity and functional impairment. A number of 
markers are taken into consideration according to 
clinical appropriateness, such as angiotensin convert- 
ing enzyme (ACE), 67Ga uptake (total body), lym- 
phocyte alveolitis > 14% in bronchoalveolar lavage 
fluid, 10% or more reduction from previous values in 
vital capacity or 15% or more in alveolar diffusion 
(DLCO), increasing dyspnoea or cough, worsen- 
ing chest X-ray, extrapulmonary disease such as 
uveitis, lupus pernio, hypercalcemia, hypercalciuria, 
myocardial disease or others. 
PATIENTS 
Between 1987 and 1992, 356 new patients with histo- 
logically proven sarcoidosis were seen by the authors; 
116 needed long-term corticosteroid therapy, many of 
them after a period of observation without therapy, 
but 33 were excluded because they were already under 
treatment, or had been treated with corticosteroids 
before reaching the authors’ Sarcoid Clinic. Fifteen 
further patients were excluded because their z-score 
was - 2 or less. Most of the 48 patients excluded 
were treated with DFZ and have already been 
described in a previous paper (7). 
Sixty-eight patients satisfied the admission criteria 
for the present trial. Four more meeting these admis- 
sion criteria had already been in follow-up at the 
Clinic since before 1987, but the indication for corti- 
costeroid therapy had arisen only in 1987 or later. 
These 72 patients all gave informed consent and 
were enrolled and allocated at random to PDN (36 
patients) or DFZ (36 patients). They form the basis of 
the present report. The study was scheduled to last at 
least 24 months. Since enrolment took 5 yr, some 
patients had been followed-up for up to 7 yr when the 
trial was closed in December 1994. 
As already stated (7,9), the authors do not believe 
in a rigid protocol because starting dose, subsequent 
doses and time of therapy must be adapted to each 
individual clinical situation. For this reason, the 
LONG-TERM EFFICACY AND SAFETY OF CORTICOSTEROIDS 45 I 
TABLE 1. Baseline characteristics of patients at recruitment 
Deflazacort Prednisone 
n 
Sex 
Postmenopausal 
Age, years* 
Sarcoidosis involvement 
Pulmonary only 
Pulmonary and extrapulmonary 
Extrapulmonary only 
Disease duration, years* 
Course of disease at recruitment 
Steady 
Worsening 
Recent evaluation? 
VCMC, mg k,HPO, ml- ’ 
Estimated value1 
36 36 
16 F/20 M 17 F/19 M 
8 6 
40.0 f 11.5 40.8 f 11.0 
17 18 
17 15 
2 3 
5.6 I!C 4.7 3.5 zt 4.6 
6 5 
24 25 
6 6 
130.0 f 4.8 129.8 & 5.6 
*Mean * SD. 
~-TOO few data in the patient history to understand whether the course is steady, worsening 
or improving. 
iMean f SE (n=58 patients available for the long-term bone study: 30 deflazacort, 28 
prednisone). 
study was not performed under blind conditions. In 
most cases, the starting dose was 12.540 mg PDN 
daily, or 1548 mg DFZ. Maintenance doses and 
duration of corticosteroid therapy were tailored to 
the individual clinical need, on the basis of frequent 
visits to the Sarcoid Clinic, at least once every 2 
months in the first year and at least every 4 months 
thereafter. During these visits, symptoms, compliance 
with the treatment and side-effects of therapy were 
evaluated, and a physical examination was done; 
suggestions were given about the next dose of therapy 
and the next work-up. 
No other drugs known to affect bone metabolism 
were allowed. Whenever severe bone loss was devel- 
oping or fractures occurred, corrective and preventive 
drug strategies were set up (e.g. oestrogens, calci- 
tonin, diphosphonates, etc.). From that moment 
onwards, the patient receiving these drugs was no 
longer evaluable for bone toxicity analysis. 
DISEASE ACTIVITY AND LUNG FUNCTION 
MARKERS 
The work-up included periodic checks of the criteria 
for sarcoid activity and functional impairment to 
assess the efficacy of the drugs, and a biochemical and 
haematological profile plus periodic bone mineral 
content evaluation to assess their safety. Chest X-rays 
were taken in the postero-anterior projection and 
were classified according to the radiographic stage: 
Stage 0 was a normal chest film; Stage I had hilar 
adenopathy alone; Stage II had hilar adenopathy 
and parenchymal infiltrates, and Stage III had paren- 
chymal infiltrates only. 67Gallium lung scan, based on 
the uptake of 67Ga, was assessed by a subjective 
method, using a O-3 score as described previously (10). 
Serum ACE was measured by a radiometric method 
(11); normal values in the authors’ laboratory are 
34-125 U 1 - I. Serum and urine calcium levels were 
followed to gain further information on the disease 
activity in a study whose primary focus was on bone. 
Pulmonary function tests consisted of standard 
spirometry [forced vital capacity (FVC) and forced 
expiratory volume in 1 s (FEV,] and the diffusing 
capacity of the lungs for carbon monoxide (DLCO); 
gas analysis of an arterial sample was carried out 
when low FVC or DLCO raised doubt about low 
PaO,. Techniques and normal values have been 
described previously (12). 
Chest radiography, lung function and disease 
activity markers were assessed at least every 4-6 
months in the first year and from 6 months to 1 yr 
thereafter; some patients had more frequent controls 
according to clinical needs. 
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SAFETY 
Safety was assessed on the basis of a biochemical 
profile including urea nitrogen, creatinine, aspartate 
and alanine aminotransferases, glutamyltransferase, 
total proteins and protein fractions, sodium, potass- 
ium, bilirubin and urinanalysis; the haematological 
profile included haemoglobin, haematocrit, red and 
white blood cell counts, differential count and plate- 
lets. All these markers were measured at recruitment 
and then at least once a year according to clinical 
needs. Body weight and systolic and diastolic blood 
pressure were recorded at each visit. 
Steroid wasting effects on bone were assessed by 
measuring trabecular bone mineral density of the 
lumbar spine by single energy QCT with a Siemens 
Somaton 2CT Scanner (with antropomorphic calibra- 
tion phantom), as described previously (13). Verte- 
bral cancellous mineral content (VCMC) was 
scheduled to be measured yearly, at least three times 
during the trial: a’t enrolment, and after 1 and 2 yr. 
Since enrolment lasted 5 yr, some patients had had 
more than three QCT assessments (up to eight) when 
the study was closed in December 1994. 
The assessment of fracture events was based on the 
periodical (6-monthly) radiological examination of 
the ribs and thoracic spine, and also according to 
necessity. Radiographs were examined separately by 
two experienced readers (blinded to the clinical his- 
tory). The definition of vertebral fracture, as opposed 
to vertebral deformity, remains controversial (1416). 
Bearing in mind the doubts raised by Kleerekoper 
(14), a vertebral fracture was defined as a reduction of 
at least 15%, or an absolute decrease of at least 4 mm, 
on a lateral spine film, in the anterior, middle or 
posterior height of any vertebral body between base- 
line and follow-up (16,17). Only new deformities of 
vertebrae considered to be normal in the initial radio- 
graph were ‘counted as incident fractures (17). Wedge 
fractures were defined by anterior height reduction, 
and crush fractures by posterior height reduction 
(17). 
STATISTICS 
The required sample size was computed by consider- 
ing bone mineral loss as primary variable. For pre- 
fixed risks of type I equal to 0.05, 26 patients per 
group are sufficient to detect a true between-drugs 
difference in bone loss per year equal to or higher 
than one standard deviation of individual bone loss 
per year, with a test power of 95% or more. Since a 
large number of drop-outs and protocol violations 
were expected, a sample size of 36 patients per group 
was chosen. 
Between treatment-groups differences in basal con- 
ditions of categorical variables (such as sex, meno- 
pausal status, disease involvement and duration) were 
tested by Fisher’s exact test (18,19). The time course 
profiles of safety and efficacy markers were fitted by 
an ANOVA model for parallel group design with 
repeated measures (20). Since only a few observations 
were made after the fourth year of therapy, the 
analysis was limited to the first 4 yr. 
The following null hypotheses were tested: no 
difference between treatment-groups in basal values; 
no difference in trend and quadratic departure from 
linearity between treatment-groups; and no trend 
and quadratic departure from linearity within either 
treatment group. 
Profiles of safety and efficacy data were reported as 
least-squares means ( f SE) (21), based on the model 
and thus adjusted for the confounding effects of 
missing data. Bone wasting effects were expressed 
as VCMC loss (mg K,HPO, ml - ‘) yr - I. This 
was estimated from the whole profile of three or 
more QCT assessments per patient by means of the 
following linear model: 
Yj(t)=Ui+ Bi ’ lOg,(t+ l)+ &i(t) 
where yi(t) is the VCMC recorded at time t (months) 
on the ith patient, constants Ui and pi are the intercept 
and the slope (i.e. VCMC loss rate) of the above 
function for the ith patient, and q(t) is the random 
term (biological and technical variability) associated 
with yxt). The average VCMC loss curves for DFZ 
and PDN were obtained as mean-constant (a, B> 
curves from the individual curves. The first derivative 
of mean-constant curves 
ay(t)lat= /Y(t+ 1) 
provides an expression for VCMC loss velocity. 
Goodness of fit of the above model was evaluated 
by analysis of residuals (observed value-predicted 
value) (22). The estimated VCMC loss takes into 
account all QCT assessments; thus, it is expected to 
be somewhat more reliable and precise than the loss 
computed as the difference between the basal and the 
last QCT assessments. 
Data management and analysis were carried out 
using the SAS@ statistical analysis system (Version 
6.03) (23). 
Results 
The baseline characteristics of the 72 patients 
are outlined in Table 1. There were no significant 
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TABLE 2. Extrapulmonary sarcoidosis requiring therapy 
Deflazacort Prednisone 
n 
Liver 
Skin 
Heart 
Renal stone 
Hypercalciuria >400 mg per 24 h (without stone) 
Uveitis 
Bone 
Central nervous system 
Spleen 
Joints 
Coexisting pulmonary impairment 
19 18 
5 7 
5 4 
2 2 
4 4 
3 6 
4 1 
2 0 
2 0 
2 1 
1 1 
17 15 
Localizations (peripheral lymphnodes or mild skin lesions) not requiring therapy are not 
indicated. 
differences between the two groups as regards age, 
sex, disease duration or course at recruitment, or 
initial VCMC, although disease duration was some- 
what less in the PDN group. VCMC refers only to the 
58 patients (30 DFZ, 28 PDN) available for the long- 
term bone study (see later), but the values were nearly 
the same when considering all 72 patients. 
Extrapulmonary involvement requiring therapy 
was observed in 37 patients, 19 in the DFZ group and 
18 in the PDN group (Table 2). In all but five, the 
TABLE 3. Disease markers at recruitment 
extrapulmonary involvement was associated with pul- 
monary impairment, also requiring therapy. There 
were nine cases of lupus pernio, four of arrhythmias, 
one of hemiparesis, one of seizures plus bilateral optic 
nerve atrophy, and three of hypersplenism. 
Table 3 shows the disease markers at recruitment; 
as expected, chest X-ray was Stage II or III in the 
majority of cases. There were no differences between 
the two groups, although the 24-h calciuria appeared 
higher (PzO.08) in the PDN group. 
Deflazacort Prednisone P 
Chest X-ray stage 
I 
II 
III 
0 
67Ga lung scan (score) 
FVC (% predicted) 
FEV, (‘! predicted) 
DLCO (%I predicted) 
PaO, (mmHg) (n=30 vs 30) 
S-ACE (U 1- ‘) 
Serum calcium (mg dl- ‘) 
Urinary calcium (mg per 24 h) 
4 3 
14 16 
16 14 
2 3 
1.75 It 0.15 1.39 ck 0.15 
87.1 St 2.8 82.6 + 2.8 
84.3 zk 3.0 80.9 + 3.0 
77.7 It 3.8 81.0 + 3.6 
84.5 zt 1.6 85.5 + 1.6 
127.6 zt 9.3 128.5 i 9.1 
9.6=tO.l 9.6 + 0.1 
270.1 k 28.3 344.8 z!z 27.5 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s., not significant, FVC, forced vital capacity; FEV,, forced expiratory volume in 1 s; 
DLCO, alveolar diffusion; PaO,, arterial oxygen tension; S-ACE, serum angiotensin 
converting enzyme. 
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TABLE 4. Trial duration and mean daily doses of corticosteroids in the whole period and 
during each year from trial’s beginning 
Deflazacort Prednisone 
Duration (months, mean f SD) 
Mean ( f SD) daily dose, mg 
Whole period (n = 36 vs 36) 
First year+ = 36 vs33) 
Second (n = 3 1 vs 28) year 
Third (n= 27 vs 19) year 
Fourth (n= 14 vs 10) year 
42.0 dz 18.7 31.7 f 17.7 
14.8 zt 9.6 10.4 h 6.1 
21.5 f 9.5 14.4 f 7.6 
15.4 & 9.9 11.6 f 5.8 
9.7 It 5.1 7.3 f 6.1 
9.3 f 5.8 8.6 zt 5.7 
Table 4 shows the trial duration and the mean daily 
doses of corticosteroids used during the whole trial 
and during each year. Sixty-nine patients completed 
1 yr of trial, 59 patients completed 2 yr, 46 patients 
completed 3 yr, and 24 patients completed 4 yr or 
more (up to 7 yr). The mean duration ( f SE) of the 
trial was 3.5 f 1.56 in the DFZ and 2.6 f 1.48 yr 
in the PDN group. Daily starting doses of cortico- 
steroids (mean f SD) were 22.3 f 6.9 mg for PDN and 
23.2 f 1 l-4 mg for DFZ. The doses were progres- 
sively reduced from the first to the fourth year of 
therapy, and the drugs could be stopped in 19 
patients. Mean daily doses from the start of the trial 
to the last record were 10.4 f 6.1 mg PDN and 
14% f 9.6 mg DFZ. 
Compliance was generally good, with few excep- 
tions (see later). Sixteen patients (11 PDN, five DFZ) 
were lost to follow-up: three (all PDN) during the first 
year; 10 (five per group) during the second year, and 
one each during the third, fourth and fifth years (all 
PDN). The reasons were unknown for five patients 
(three DFZ, two PDN), four patients moved to 
another region (one DFZ, three PDN), three patients 
were uncooperative or had poor compliance (all 
PDN), one patient had transport problems (DFZ: the 
patient with bilateral optic nerve atrophy was blind), 
one patient had family problems (divorce) (PDN), 
and two patients stopped because of fear of side- 
effects (both PDN). Four further patients, all in the 
PDN group, interrupted the trial because of side- 
effects, three during the third year and one during the 
fourth year (see later); two were shifted to DFZ, 
which was well tolerated and is still being given, and 
the other two are still without therapy. 
In 19 patients (12 DFZ, seven PDN), therapy was 
stopped because it was judged to be no longer neces- 
sary: four patients (three DFZ, one PDN) during the 
third year, 10 patients (five per group) during the 
fourth year, four patients (all DFZ) during the fifth 
year, and one patient (PDN) during the seventh year. 
All these patients are still being followed-up, and two 
patients (one per group) have been given therapy 
again because of relapse. Thirty-three patients (or 37 
including the two patients who restarted therapy and 
the two patients shifted from PDN to DFZ) were still 
under therapy in December 1994, when the trial was 
closed in five patients (one DFZ, four PDN) after 
more than 2 yr, 10 patients (eight DFZ, two PDN) 
after more than 3 yr, and 18 patients (10 DFZ, eight 
PDN) after more than 4 yr. When the trial was 
closed, current daily doses ranged from 6 to 18 mg 
DFZ and from 5 to 20 mg PDN. 
While drug-related adverse events are described 
(see later) for the total duration of the trial, the yearly 
results are statistically analysed only for the first 4 yr 
in view of the small number of patients followed-up 
for more than 4 yr. 
The results regarding sarcoid activity parameters 
indicate a good response to treatment. Chest X-ray 
showed complete recovery in 26 patients (13 per 
group), and good improvement in 30 (15 per group). 
At final record, it was unchanged from baseline in 
eight patients (five DFZ, three PDN) and worse in 
two (one per group). It remained Stage 0 throughout 
the trial in five patients (two DFZ, three PDN), and 
could not be verified in one patient because of early 
drop out. 67Gallium improvements are shown in Fig. 
1. The score dropped significantly in 4 yr treatment in 
both groups: DFZ from 1.75 & 0.15 to 1.10 f 0.23, 
PcO.05; and PDN from 1.39 f 0.15 to 0.53 f 0.32, 
P=O*O5. The decrease was even more striking in the 
first year of treatment, when the corticosteroid dose 
was higher; the improvement was similar in the 
two groups, with no significant difference (P>O.O5). 
Angiotensin converting enzyme profiles (Fig. 2) also 
showed significant improvements with both drugs, 
without any significant difference between the two 
groups. Calciuria dropped from the recruitment val- 
ues set out in Table 3 to 186.6 f 47.1 (PcO.05) in the 
PDN group and 207.4 f 39.9 in the DFZ group, after 
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0.6 
0.4 
0.2 
\ 
\ 
D* 
P+ 
4 
1 2 3 4 
Year 
FIG. 1. Time course of 67Ga lung scan score 
(mean f SE. - - -, prednisone; -, deflazacort . 
*P<O,O5 vs baseline, TP=O.OS vs baseline. The 
number of patients at the end of each year is shown 
in Table 4. 
4 yr of therapy. The FVC profiles are described in 
Fig. 3: the improvement was significant (PcO.01) with 
both drugs. FEVi reached 87.8 f 2.4% predicted in 
the DFZ group, and 84.4 f 2.7% in the PDN group 
after 4 yr of therapy; these differences from basal 
values were not significant. DLCO improved, though 
also not significantly, after 1 yr to 85.7 f 3.3% pre- 
dicted in the DFZ group, and 93.1 f 3.1% in the 
PDN group; the values remained good, although 
lower, after 4 yr, when the dose was lower, averaging 
82.9 f 4.0 in the DFZ group, and 83.9 f 4.9 with 
PDN. PaO, changes from baseline were not signifi- 
cant over the years: PaO, averaged 85.8 f 2.1 mmHg 
in the DFZ group at the end of the trial and 82.1 * 
2.6 in the PDN group. No changes were observed 
in serum calcium, which was normal at baseline in 
all cases. 
The only significant changes in haematological or 
biochemical parameters, and in body weight, are 
shown in Table 5. In spite of these changes, the only 
significant difference between the two groups was in 
body weight, which increased significantly in the 
1 2 3 4 
Year 
FIG. 2. Time course of serum angiotensin convert- 
ing enzyme (ACE) (mean If SE) (normal values: 
34-l 25 U 1 - ‘) - - -, prednisone; -, deflazacort. 
*P<O.O5 vs baseline, t PcO.01 vs baseline. The 
number of patients at the end of each year is shown 
in Table 4. 
1 2 3 4 
Year 
FIG. 3. Time course of forced vital capacity (FVC) 
(mean f SE). - - -, prednisone; -, dellazacort. 
*P<O.Ol vs baseline. The number of patients at the 
end of each year is shown in Table 4. 
PDN group as compared to the DFZ group 
(PcO.01). Heart rate and systolic or diastolic blood 
pressure changes were unremarkable in both groups; 
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TABLE 5. Time-course profiles of body weight and haematological and biochemical parameters 
Parameter Baseline First year Second year Third year Fourth year P 
Body weight 
DFZ 
PDN 
Blood lymphocytes ( lo3 ,~l- ‘) 
DFZ 
PDN 
Serum sodium (mmol I- ‘) 
DFZ 
PDN 
Serum potassium (mm01 1 - ‘) 
DFZ 
PDN 
70.1 f 0.4 72.1 f 0.5 71.8 f 0.4 69.9 f 0.6 70.0 xt 0.6 0.202 
69.9 f 0.4 72.0 f 0.5 73.4 f 0.5 72.2 2~ 0.5 73.6 A 0.8 0.00 1 
1.88 k 0.08 1.92 k 0.09 
1.81 f 0.08 1.96 & 0.10 
1.94 f 0.09 1*87&O-11 
1.91 i 0.10 2.24f0.11 
2.30 f 0.14 0.040 
2.13 f 0.18 0.039 
140.3 f 0.6 139.4 f 0.6 139-8 f 0.6 140.2 f 0.7 142.5 f 0.9 0.040 
139.0 f 0.6 140.5 f 0.6 140.3 f 0.7 140.7 f 0.9 139.4 f 1.3 O-768 
4.39 f 0.05 4.23 f 0.05 4.13 f 0.05 4.03 f 0.07 
4.44 f 0.05 4.06 f 0.05 3.93 f 0.06 4.05 f 0.08 
4.15 f 0.08 0.003 
4.04Ito.11 0.005 
DFZ, deflazacort; PDN, prednisone. 
Values expressed as least squares mean zt within individual SE. 
P denotes the probability for the hypothesis of no increasing or decreasing trend from trial’s start to the fourth 
year of therapy (in each treatment group). 
blood pressure rose above the upper threshold (140/ 
90) in two DFZ patients and in three PDN patients. 
Table 6 shows the drug-related adverse events that 
first occurred or worsened after starting therapy. The 
only severe side-effects were two episodes of pneu- 
monia (DFZ) and one case of melena (PDN). One 
PDN patient had bilateral posterior subcapsular 
cataract and underwent bilateral lens implantation, 
and two DFZ patients had posterior cataract; nobody 
had visual loss. 
The timing of drug-related adverse events differed, 
with most of the metabolic and nutritional side-effects 
TABLE 6. Drug-related adverse events 
Deflazacort Prednisone 
II 
Metabolic and nutritional 
(weight gain, facies lunaris, abdomen striae, 
face hypertrichosis, Na or K disorders) 
Gastrointestinal tract disorders 
(dyspepsia, gastritis, abdominal pain, melena) 
Hypertension 
Serious infections (pneumonia) 
Limb oedema 
Diabetes 
(hyperglycemia > 140 mg dl - ‘, glycosuria) 
Reproductive system 
(amenorrhea, dismenorrhea, menorrhagia, 
loss of libido) 
Cataract 
Nervousness 
Bone fractures 
&Bone pain 
36 36 
15 25 
4 9 
1 2 
1 
1 
6 
10 
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appearing in the first months of therapy, whereas 
cataract and skeletal disorders (see later) were late 
complications. Cataract appeared after 2 yr of PDN 
therapy in the patient who underwent bilateral lens 
implantation, and after 3 yr of DFZ therapy in two. 
All but one of the fractures occurred 3-5 yr after 
beginning therapy, in spite of the well-known early 
drop of BMC in the first months of coiticosteroid 
therapy. 
Four drug-related drop-outs due to side-effects 
were reported in the PDN group, all more than 2 yr 
after beginning therapy. The causes were bone pain, 
accompanied by a severe reduction of BMC in two, 
dyspepsia in one, and body weight gain (11 kg) in one; 
two of these four patients were shifted to DFZ, which 
was tolerated better and is still being given to both. 
BONE TOXICITY ANALYSIS 
Of the 36 patients enrolled in each treatment group, 
five given DFZ and eight given PDN were not 
evaluable for bone toxicity analysis, since they had 
only one or two QCT assessments. One other DFZ 
patient was excluded because she underwent hyster- 
ectomy 6 months after the study started. To sum up, 
30 patients in the DFZ group and 28 in the PDN 
group met the requirements for analysis of bone mass 
loss. Their demographic and clinical characteristics 
at recruitment were well matched in the two groups 
with no noteworthy differences with regard to age, 
sex, body weight, postmenopausal status, pulmonary 
and extrapulmonary involvement, radiological stage, 
duration of disease and initial VCMC. 
Limiting the observation to the above patients, the 
trial lasted 32.4 & 8.7 (SD) months (DFZ group) and 
31.6 f 8.5 months (PDN group); the range for both 
groups was 2-6 yr. The mean daily dose during each 
year from the start to the fourth year was similar to 
that shown in Table 4 for the whole group of patients. 
The dose decreased progressively in both groups year 
by year, and the dose ratio DFZ:PDN (mg/mg) 
ranged from 0.96 at the second year to 1.35 at the 
third year, thus confirming that the doses of DFZ and 
PDN had been titrated in order to obtain the same 
desired therapeutic response. 
At the end of the trial, 21 patients (12 DFZ, nine 
PDN) are no longer taking corticosteroids. The 
others are taking a daily maintenance dose of 
7.9 i 2.9 mg of DFZ (18 patients) or 9.3 * 4.6 mg of 
PDN (19 patients), and will probably be continuing 
this treatment for a long time yet. With this dose, they 
are under control with stability or improvement of 
symptoms and of the most important parameters. 
Figure 4 shows the average bone mass loss 
curves for DFZ and PDN together with the average 
100 
1 
I I I / 
u 1 2 3 4 
Year 
FIG. 4. Mean VCMC loss (mg K,HPO, ml - ‘) for 
deflazacort (- - -) and prednisone ( -) f SE (. . . .), 
and mean residuals (0, 0). The difference between 
the two curves is statistically significant (P=O.O33). 
The horizontal line at the level of 110 mg K,HPO, 
eq represents the fracture threshold (38). 
residuals from the individual curves. Mean residuals 
are lower than 2% of the fitted values, indicating that 
the bone mass loss model fits observed data satisfac- 
torily. During the 4 yr under study, BMC dropped 
from 129.8 + 5.6 mg K2HP0, ml ~ ’ to 106.7 & 5.4 in 
the PDN group, and from 130.2 f 4.8 to 115.6 f 5.2 
in the DFZ group. This implies a mean loss of 18 
(PDN) vs 11% (DFZ); PcO.05. 
The mean VCMC loss velocity per year was about 
1.6 times higher in the PDN than the DFZ group 
(PcO.05) (Table 7). VCMC loss velocity was 
decreased from the beginning to the end of the trial; 
from about - 5.5 * 0.7 mg K,HPO, ml - ’ yr - ’ in 
PDN group and - 3.4 f 0.6 in DFZ group at the end 
of the first year of treatment, to only - 1.4 & 0.32 in 
the PDN group and - 0.9 * 0.2 in the DFZ group at 
the end of the fourth year. 
VCMC loss velocity was significantly higher with 
higher glucocorticoid doses (PcO.01) (Fig. 5) and 
TABLE 7. Mean VCMC loss velocity* at the end of the 
first 4 y therapy 
Year Deflazacort Prednisone 
1 - 3.45 f 0.60 - 5.48 + 0.71 
2 - 1.79 rt 0.31 - 2.85 * 0.37 
3 - I.21 z!z 0.21 - 1.92 f 0.25 
4 - 0.92 f 0.16 - 1.45 * 0.19 
*mg K2HP04 ml - ’ yr - ‘, mean & SE. 
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FIG. 5. Scatterplot and regression lines of VCMC 
loss (mg K,HPO, ml - ‘) vs mean daily dose (mg 
day - ’ kg - ’ of body weight) over the whole study. 
0, ~ prednisone. 0, ---, deflazacort. The slope 
of both’regression lines is significant at 0.01 level. 
Mean VCMC loss(adjusted for doses) is signifi- 
cantly different between groups (PcO.05). 
bone toxicity tended to be higher in PDN than in 
DFZ patients (PcO.05). Twelve patients in the PDN 
group and only six in the DFZ group had bone mass 
loss higher than 20 mg K,HPO, ml - ‘. 
In addition, the occurrence rate of skeletal frac- 
tures from minimal trauma was six events (rib, epi- 
trochlear, two vertebral crush and two vertebral 
wedge fractures) in five PDN-treated patients (one 
with two wedge fractures) and one event (vertebral 
crush fracture) in one DFZ-treated patient. All but 
one of the fractures occurred after 3 or more years of 
therapy, in agreement with the shape of the PDN 
curve in Figure 4; while the DFZ curve (mean - SE) 
remains above the level of 110 mg K,HPO, ml - ‘, 
which is considered the fracture threshold (24), the 
mean PDN curve goes below the threshold after 
2.3 yr of therapy, suggesting that after that time, a 
number of fractures are to be expected, mainly in the 
PDN group. Three of the six patients with fractures 
had a z-score near to - 2 at recruitment. 
Light to severe bone pain was reported in 10 PDN 
and two DFZ patients, in addition to those who 
developed skeletal fractures, and eight PDN vs two 
DFZ patients had to start corrective measures 
(bisphosphonates, calcitonin or oestrogens) for their 
bone loss. 
Discussion 
Chronic PDN at a daily dose of 5-l 5 mg is associated 
with serious adverse effects (25,26), and therapy will 
probably be required for life by many patients with 
sarcoidosis. In such a situation, the search for a cor- 
ticosteroid with lower side-effects is of major interest. 
These results confirm that the efficacy of DFZ is 
comparable to that of PDN. Similar results were 
found in a 6-month trial (8). This has also been 
observed in other diseases over periods ranging from 
12 to 15 months (l-4). In this trial, some rebound to 
positivity in the 67Ga scan profile may be observed 
after the second year (Fig. 1, DFZ curve); similarly, a 
small drop in DLCO was observed after the third 
year. The reason probably lies in the reduction of 
corticosteroid dosage over the years which permitted 
the sarcoid activity to reemerge. However, the 
authors’ aim was not so much to improve the 67Ga 
images as to preserve respiratory function, and in fact 
FVC and DLCO did remain at acceptable levels. A 
second reason may be that only severely impaired 
patients are willing to comply with frequent tests over 
a long period, so that there may be some selection of 
the most severely diseased patients. 
As regards safety, haematological and biochemical 
variables did not show clinically important changes in 
either group, but most patients had drug-related 
adverse events, more frequent in the PDN group. 
Since there are no other reports of controlled trials 
longer than 15 months for DFZ, there were no terms 
of comparison. However, these results are in agree- 
ment both with the better safety of DFZ than PDN 
observed in shorter, double-blind trials (24) and with 
the authors’ previous study on DFZ (7). 
The most frequent side-effect was weight gain, 
reported by 19 of the 72 patients (26.3%). A similar 
observation was described by Johns (27), who noted 
weight gain in 24% of a series of 171 sarcoid patients 
with mean PDN treatment of eight years. Patients 
dropped out on account of adverse events in the PDN 
group alone. 
The most disabling adverse event was skeletal 
fractures. Generally, corticosteroids indirectly affect 
bone mass by reducing gastrointestinal calcium 
absorption thereby increasing parathyroid hormone 
activity (28). The present findings are in good agree- 
ment with those indicating that bone loss occurs 
rapidly, within the first 6-12 months of glucocorticoid 
therapy, after which the rate of bone mass loss 
declines more slowly (29,30). Atraumatic fractures 
did not occur until after 2 or more years of therapy, 
when mean VCMC dropped below the atraumatic 
fracture threshold. Similarly, Adinoff and Hollister 
(31) reported that all their asthmatic patients with 
fractures had received prednisone for at least 3 yr 
before the first fracture. 
These data confirm that a low initial VCMC is an 
important risk factor for fractures; reduced bone 
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mineral density was the strongest predictor for frac- 
tures in other studies too (17,32). It is now known 
that it is probably wise to protect patients with an 
initial z-score of - 1.5 or less and needing steroids 
with corrective measures, avoiding their inclusion in 
this trial. However, this was not so clear when the 
trial was started in 1987. 
Prospective longitudinal studies are few, but these 
data (mineral loss 11% in the DFZ group vs 18% in 
the PDN group during 4 yr of treatment) are in 
agreement with published reports. As regards the 
effects of steroid doses and treatment duration on 
the extent of bone mass loss, data are contradictory 
mainly because the range of doses administered may 
be too narrow and the duration of treatment too 
short to detect any consistent relationship with bone 
mass loss. In the present trial, mean daily doses are 
fairly evenly scattered between 0.05 and 0.35 mg 
kg- ’ day-‘, and treatment duration ranged uni- 
formly between 18 and 48 months. Therefore, this 
study formed a definite correlation between dose 
and VCMC loss (Fig. 5) despite the wide intra- and 
inter-individual variability. 
However, vertebral mineral density loss was signifi- 
cantly (PcO.05) greater in the PDN than the DFZ 
group over the whole period of treatment. 
The bone loss indicated a constant bone toxicity 
ratio, PDN:DFZ of about 1.6. The higher bone 
toxicity of PDN emerges both at low and high doses. 
After 3 yr continuous treatment, both bone loss and 
atraumatic fractures were more evident in patients 
treated with PDN (six events in five patients) than 
in patients treated with DFZ (one case). Moreover, 
the mean curve of DFZ, unlike the PDN one, did 
not reach the fracture threshold during the trial. 
This suggests that the lower rate of bone loss 
during treatment with DFZ may lower the risk of 
spontaneous fractures. 
In conclusion, this trial confirms the comparable 
efficacy of DFZ and PDN in the long-term therapy of 
chronic sarcoidosis. Skeletal, metabolic, nutritional 
and gastrointestinal tract disorders appeared more 
frequently in PDN-treated patients. 
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